New Study Highlights Whisper Device's Safety in Circulatory Support

Whisper Device Outperforms Impella CP in Recent Study

The recent findings demonstrate that the Whisper™ device by Second Heart Assist Inc. offers significantly lower hemolysis compared to the well-known Impella CP device. This pivotal study utilized sophisticated testing methods, as established by the FDA and the American Society for Testing and Materials, to evaluate the performance of these medical devices under controlled conditions.

Details of the Study Conducted

This comprehensive research took place at the Texas Heart Institute, which tested the effectiveness of five Whisper™ devices against a comparable Impella CP device. The Whisper™ device was assessed at a speed of 10,000 RPM, while the Impella CP was tested at a much higher speed of approximately 44,133 RPM to match the Whisper's output. The Whisper™ typically operates at lower speeds of around 7,000 to 7,500 RPM, maintaining the essential pulsatility of the heart while also ensuring adequate blood flow.

Key Findings on Hemolysis

The analysis utilized the tetramethylbenzidine method to assess plasma free hemoglobin levels, a crucial metric for understanding hemolysis. Results showed that the Whisper™ device exhibited not only a stunning reduction in plasma free hemoglobin but also excelled in both normalized and modified index of hemolysis measures when compared to the Impella CP.

Clinical Implications of the Whisper Device

The implications of these remarkable results suggest that the Whisper™ device could provide a safer option in clinical scenarios where high performance is critical. This is particularly relevant for procedures where the support duration exceeds one hour, as excessive hemolysis can lead to severe complications like acute kidney injury (AKI).

Advanced Design of the Whisper™ Device

Besides its proven efficiency, the study highlights that the design of the Whisper™ device addresses significant areas of concern associated with other 'micro-axial' pumps. These pumps often deal with complications stemming from their geometric configurations and high shear rates that can lead to hemolysis. The research illustrates that the Whisper's advanced technology outshines prior designs, positioning it as a potential leader in the market for mechanical circulatory support devices.

About Second Heart Assist Inc.

Second Heart Assist Inc. is spearheading the development of an innovative temporary percutaneous mechanical circulatory support (MCS) system that features a motorized impeller within a stent cage. This device aims to assist patients suffering from acute decompensated heart failure (ADHF) and improve outcomes for those facing diuretic resistance, persistent congestion, and cardiogenic shock.

The Future of Circulatory Support

It is important to note that while the Whisper™ device shows immense potential, it is still in the development phase and is not yet available for clinical use or sale. This focus on advancement highlights Second Heart Assist's commitment to improving the safety and effectiveness of circulatory support technologies.

Frequently Asked Questions

What is the Whisper™ device?

The Whisper™ device is a next-generation percutaneous mechanical circulatory support system designed to aid patients with severe heart failure.

How does the Whisper™ device compare to Impella CP?

The Whisper™ device has been shown to cause significantly less hemolysis compared to Impella CP, making it a safer alternative in clinical settings.

What were the findings of the recent study?

The study found that the Whisper™ device had a lower change in plasma free hemoglobin and significantly better hemolysis indices than Impella CP.

What are the clinical implications of these findings?

The findings suggest that the Whisper™ device may reduce risks associated with hemolysis, particularly in prolonged therapeutic scenarios.

When will the Whisper™ device be available?

The Whisper™ device is currently in development and is not yet available for use or sale in any market.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.